US Pharma MarketingFetal gene therapy inches closer. Will embryo editing follow?
Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing the genes of human embryos. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
BOSTON — Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing the genes of human embryos.
For the most part, they are still too ...
Source: Endpoints News